Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia

Critical Care Medicine

Volumn 39, Issue 8, 2011, Pages 1866-1870

  Kox, Matthijs ^a,b   De Kleijn, Stan ^b   Pompe, Jan C ^a   Ramakers, Bart P ^a,b   Netea, Mihai G ^b   Van Der Hoeven, Johannes G ^a,b   Hoedemaekers, Cornelia W ^a,b   Pickkers, Peter ^a,b  

^a Department of Intensive Care Medicine ^*  (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Endotoxin; human endotoxemia; inflammation; interleukin 1 receptor antagonist; interleukin 10; interleukin 6; lipopolysaccharide; tolerance; transforming growth factor ; tumor necrosis factor

Indexed keywords

ENDOTOXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIAL KINETICS; BLOOD; CARBOHYDRATE TOLERANCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTOXEMIA; ENZYME BLOOD LEVEL; ESCHERICHIA COLI; EX VIVO STUDY; HEART RATE; HEMODYNAMICS; HUMAN; IN VIVO STUDY; INFLAMMATION; INTENSIVE CARE UNIT; KINETICS; LEUKOCYTE COUNT; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; TEMPERATURE;

EID: 79961054751     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182190d5d     Document Type: Article

References (36)

1. Biswas SK, Lopez-Collazo E: Endotoxin tolerance: New mechanisms, molecules and clinical significance. Trends Immunol 2009; 30:475-487
2. Brint EK, Xu D, Liu H, et al: ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004; 5:373-379 (Pubitemid 38500085)
3. Ertel W, Kremer JP, Kenney J, et al: Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85:1341-1347
4. Foster SL, Hargreaves DC, Medzhitov R: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007; 447:972-978 (Pubitemid 46975746)
5. de Vos AF, Pater JM, van den Pangaart PS, et al: In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol 2009; 183:533-542
6. Draisma A, Dorresteijn M, Pickkers P, et al: The effect of systemic iNOS inhibition during human endotoxemia on the development of tolerance to different TLR-stimuli. Innate Immun 2008; 14:153-159
7. Fitting C, Dhawan S, Cavaillon JM: Compartmentalization of tolerance to endotoxin. J Infect Dis 2004; 189:1295-1303 (Pubitemid 38457256)
8. van 't Veer C, van den Pangaart PS, van Zoelen MA, et al: Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 2007; 179:7110-7120
9. Sly LM, Rauh MJ, Kalesnikoff J, et al: LPSinduced upregulation of SHIP is essential for endotoxin tolerance. Immunity 2004; 21:227-239 (Pubitemid 39094052)
10. Netea MG, Kullberg BJ, Blok WL, et al: The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997; 89:577-582 (Pubitemid 27051694)
11. Draisma A, Pickkers P, Bouw MP, et al: Development of endotoxin tolerance in humans in vivo. Crit Care Med 2009; 37:1261-1267
12. Godin PJ, Fleisher LA, Eidsath A, et al: Experimental human endotoxemia increases cardiac regularity: Results from a prospective, randomized, crossover trial. Crit Care Med 1996; 24:1117-1124 (Pubitemid 26249360)
13. Reichenberg A, Yirmiya R, Schuld A, et al: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58:445-452 (Pubitemid 32411324)
14. Sauermann R, Marsik C, Steiner I, et al: Immunomodulatory effects of fosfomycin in experimental human endotoxemia. Antimicrob Agents Chemother 2007; 51:1879-1881 (Pubitemid 46744180)
15. Schaller G, Pleiner J, Mittermayer F, et al: Effects of N-acetylcysteine against systemic and renal hemodynamic effects of endotoxin in healthy humans. Crit Care Med 2007; 35:1869-1875 (Pubitemid 47220360)
16. Hirschfeld M, Ma Y, Weis JH, et al: Cutting edge: Repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000; 165:618-622 (Pubitemid 30484724)
17. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77:1627-1652
18. Erikstrup C, Ullum H, Pedersen BK: Shortterm simvastatin treatment has no effect on plasma cytokine response in a human in vivo model of low-grade inflammation. Clin Exp Immunol 2006; 144:94-100
19. Draisma A, de Goeij M, Wouters CW, et al: Endotoxin tolerance does not limit mild ischemia-reperfusion injury in humans in vivo. Innate Immun 2009; 15:360-367
20. Mackensen A, Galanos C, Wehr U, et al: Endotoxin tolerance: Regulation of cytokine production and cellular changes in response to endotoxin application in cancer patients. Eur Cytokine Netw 1992; 3:571-579
21. Randow F, Syrbe U, Meisel C, et al: Mechanism of endotoxin desensitization: Involvement of interleukin 10 and transforming growth factor beta. J Exp Med 1995; 181:1887-1892
22. Geissmann F, Manz MG, Jung S, et al: Development of monocytes, macrophages, and dendritic cells. Science 2010; 327:656-661
23. Serbina NV, Jia T, Hohl TM, et al: Monocytemediated defense against microbial pathogens. Annu Rev Immunol 2008; 26:421-452 (Pubitemid 351600381)
24. Swirski FK, Nahrendorf M, Etzrodt M, et al: Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325:612-616
25. Flohé S, Lendemans S, Schade FU, et al: Influence of surgical intervention in the immune response of severely injured patients. Intensive Care Med 2004; 30:96-102 (Pubitemid 38147113)
26. Dorresteijn MJ, Draisma A, van der Hoeven JG, et al: Lipopolysaccharide- stimulated whole blood cytokine production does not predict the inflammatory response in human endotoxemia. Innate Immun 2009; 6:248-253
27. Riikonen P, Saarinen UM, Teppo AM, et al: Cytokine and acute-phase reactant levels in serum of children with cancer admitted for fever and neutropenia. J Infect Dis 1992; 166:432-436
28. Steinmetz HT, Herbertz A, Bertram M, et al: Increase in interleukin-6 serum level preceding fever in granulocytopenia and correlation with death from sepsis. J Infect Dis 1995; 171:225-228
29. Netea MG, Nold-Petry CA, Nold MF, et al: Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009; 113:2324-2335
30. Kox M, van Velzen JF, Pompe JC, et al: GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation. Biochem Pharmacol 2009; 78:863-872
31. van Eijk LT, Dorresteijn MJ, Smits P, et al: Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med 2007; 35:1464-1469 (Pubitemid 46809308)
32. Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5:953-964 (Pubitemid 41746764)
33. van Deuren M, van der Ven-Jongekrijg J, Demacker PN, et al: Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 1994; 169:157-161
34. Mueller LP, Yoza BK, Neuhaus K, et al: Endotoxin-adapted septic shock leukocytes selectively alter production of sIL-1RA and IL-1beta. Shock 2001; 16:430-437 (Pubitemid 33598224)
35. Baumgartner JD, Heumann D, Calandra T, et al: Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5. J Infect Dis 1991; 163:769-772
36. Hoogerwerf JJ, Leendertse M, Wieland CW, et al: Loss of suppression of tumorigenicity 2 (ST2) gene reverses sepsis-induced inhibition of lung host defense in mice. Am J Respir Crit Care Med 2010 Oct 19. [Epub ahead of print]